A definitive cure for cancer is developed and approved within 20 years.

Question

Six frontier AI models put this at 4% by 21 Sept 2076. Full reasoning from every model.

WillHappen.ai · Accepted Answer

4% — the median of 6 frontier models, resolving by 2076-09-21.

Answer

Gemini (Google): 4% — Cancer is hundreds of distinct diseases, making a single universal therapy that permanently cures the majority biologically implausible. Permanent remission across the majority of all oncological indications requires overcoming extreme clonal and mutational diversity. FDA trials for pan-cancer targets like universal mRNA vaccines or allogeneic CAR-T still face severe toxicity and tumor escape hurdles. A breakthrough in targeting conserved pan-cancer metabolic vulnerabilities like altered glycolysis could lift odds above 10%.

Answer

Claude (Anthropic): 3% — Cancer is hundreds of distinct diseases, so one 'cure' clearing regulators for most types is biologically implausible. No oncologist or regulator frames cancer as a single disease curable by one approved therapy; heterogeneity across tumor types/genetics blocks this. Current trajectory is incremental: targeted therapies, immunotherapy, and early detection raise survival rates but don't deliver universal permanent remission. Even with 50 years of runway and accelerating biotech progress (mRNA, CRISPR, AI drug design), the 'majority of cases' bar across all cancer types is extremely high…

Answer

GPT (OpenAI): 7% — Cancer’s biological diversity makes one regulator-approved, durable cure across most cases extraordinarily hard within 50 years. FDA/EMA would need Phase III evidence of permanent remission across most major tumor types, then grant broad approval before 2076. Past breakthroughs—chemotherapy, targeted drugs, immunotherapy—improved subsets; none has produced a cross-cancer curative standard. I would raise this sharply if a platform showed durable pan-cancer cures in large randomized trials across common solid tumors by 2045.

Answer

Grok (xAI): 4% — One approved therapy must permanently remit most cancers by ~2046. Cancer comprises 200+ genetically distinct diseases; no agent has ever shown pan-cancer durable remission. FDA/EMA still require indication-specific RCTs, so a majority-of-cases claim needs unprecedented basket success inside 20 years. Prior 20-year windows produced zero such approvals; CRISPR, mRNA and AI lift the base rate only from ~0 to low single digits.

Answer

DeepSeek (DeepSeek): 3% — A single pan-cancer cure approved by 2076 is near-impossible; cancer is hundreds of diseases with distinct escape mechanisms. FDA approves drugs for specific indications, not 'cancer'; a pan-tumor cure would need one mechanism hitting every histology, which no platform has shown. Even the best current pan-tumor approvals (pembrolizumab's 2017 tissue-agnostic OK) cover ~1-4% of cases and rarely cure, so the base rate for 'majority of cancers' is… What would change my mind: a validated universal antigen plus delivery system clearing Phase III across 10+ tumor types by the 2060s, which is not on any current roadmap.

Answer

Qwen (Alibaba): 4% — Cancer is hundreds of diseases; no single mechanism will reliably cure the majority of cases within 50 years. Resolution requires permanent remission across the *majority* of cancer types—no pipeline drug targets >10% of all cancers today. Even CAR-T and checkpoint inhibitors, the most transformative classes, achieve durable remission in only select hematologic or solid-tumor subsets. A development that would change this: a universal tumor-antigen platform (e.g., neoantigen vaccine) showing pan-cancer durable responses in Phase III by ~2040.

A definitive cure for cancer is developed and approved within 20 years.

A disease-reversing cure for Alzheimer's disease receives FDA approval before 2035.

A definitive cure for at least five major cancers is approved within 10 years.

An FDA-approved universal cure for all major forms of cancer is available before 2035.

The FDA issues a decision on the drug candidate with a target date of October 9, 2026.